Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Aclaris Therapeutics, Inc. ACRS

Healthcare  —  Biotechnology
5.15 (0.23) (4.28%) as of 25 Sep
Market cap
$589.0M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Aclaris Therapeutics, Inc. (ACRS) Business Profile

Updated before January 2025

Company Overview

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies to address unmet medical needs in immuno-inflammatory diseases and dermatological conditions. Founded in 2012 and headquartered in Wayne, Pennsylvania, Aclaris has established itself as a leader in the biopharmaceutical industry by leveraging its expertise in drug discovery and development. The company was co-founded by Dr. Neal Walker, who currently serves as the President and Chief Executive Officer. Under his leadership, Aclaris has built a robust pipeline of therapeutic candidates and a strong reputation for scientific innovation.

Aclaris is supported by a team of experienced executives and researchers, including Dr. David Gordon, Chief Medical Officer, and Dr. Christopher Powala, Chief Operating Officer. Together, they bring decades of experience in pharmaceutical development, clinical research, and commercialization, driving the company’s mission to improve patient outcomes through groundbreaking therapies.

Core Business Segments

Aclaris Therapeutics focuses on two primary business segments: immuno-inflammatory diseases and dermatological conditions. The company’s pipeline includes both small molecule and biologic therapies designed to target specific pathways involved in disease progression.

Immuno-Inflammatory Diseases

Aclaris is actively developing therapies for a range of immuno-inflammatory conditions, including rheumatoid arthritis, ulcerative colitis, and alopecia areata. The company’s lead candidate in this segment is Zunsemetinib (ATI-450), an oral MK2 inhibitor currently in Phase 2 clinical trials. Zunsemetinib is designed to modulate inflammatory pathways, offering a novel approach to treating chronic inflammatory diseases.

Dermatological Conditions

Aclaris has a strong focus on dermatology, with a particular emphasis on conditions such as vitiligo, atopic dermatitis, and seborrheic keratosis. The company’s notable product in this category is Ruxolitinib Topical (ATI-1777), a JAK1/JAK2 inhibitor being developed for the treatment of atopic dermatitis. Aclaris is also exploring other dermatological indications to expand its footprint in this segment.

Business Model

Aclaris Therapeutics operates as a research-driven biopharmaceutical company, focusing on the discovery, development, and commercialization of innovative therapies. The company generates revenue primarily through licensing agreements, collaborations, and milestone payments from its partners. Aclaris also aims to commercialize its products directly in select markets, leveraging its expertise in clinical development and regulatory affairs.

The company’s business model emphasizes a balanced approach to risk and reward, with a diversified pipeline that includes both early-stage and late-stage assets. By targeting high-value therapeutic areas with significant unmet needs, Aclaris seeks to maximize its impact on patient care while delivering sustainable growth for its stakeholders.

Strategic Direction

Aclaris Therapeutics is committed to advancing its pipeline of innovative therapies and expanding its presence in key therapeutic areas. The company’s strategic priorities include:

  • Pipeline Expansion: Aclaris aims to accelerate the development of its existing pipeline while exploring new indications and therapeutic targets. The company is actively investing in research and development to identify novel drug candidates.
  • Global Reach: Aclaris plans to expand its geographic footprint by entering new markets and forming strategic partnerships with international pharmaceutical companies.
  • Sustainability Goals: The company is dedicated to minimizing its environmental impact and promoting sustainable practices across its operations. This includes reducing waste, optimizing resource utilization, and supporting community health initiatives.
  • Patient-Centric Approach: Aclaris is focused on improving patient outcomes by developing therapies that address the root causes of disease and enhance quality of life.

Competitive Landscape

Aclaris Therapeutics operates in a highly competitive biopharmaceutical market, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Pfizer Inc.: A global leader in immunology and dermatology, Pfizer offers a range of therapies for inflammatory and autoimmune diseases.
  • Eli Lilly and Company: Known for its innovative treatments in immunology, Eli Lilly competes with Aclaris in areas such as rheumatoid arthritis and atopic dermatitis.
  • Incyte Corporation: A leading biopharmaceutical company with a strong focus on JAK inhibitors, Incyte is a direct competitor in the dermatology space.
  • Regeneron Pharmaceuticals: Regeneron’s portfolio includes therapies for atopic dermatitis and other inflammatory conditions, posing a challenge to Aclaris’s market share.

Despite the competitive landscape, Aclaris differentiates itself through its focus on novel mechanisms of action and its commitment to addressing unmet medical needs.

Risk Factors

Aclaris Therapeutics faces several risks that could impact its business operations and financial performance. Key risk factors include:

  • Regulatory Challenges: The biopharmaceutical industry is heavily regulated, and delays or failures in obtaining regulatory approvals could hinder Aclaris’s ability to commercialize its products.
  • Market Dependence: Aclaris relies on the success of its lead candidates, and any setbacks in clinical trials or commercialization efforts could significantly affect its revenue.
  • Supply Chain Disruptions: The company depends on third-party manufacturers and suppliers for the production of its drug candidates. Disruptions in the supply chain could delay product development and delivery.
  • Competitive Pressure: Intense competition from larger pharmaceutical companies and emerging biotech firms could limit Aclaris’s market share and growth potential.
  • Financial Constraints: As a clinical-stage company, Aclaris may require additional funding to support its research and development activities, which could dilute shareholder value.

Recent Developments

Aclaris Therapeutics has made significant progress in advancing its pipeline and strengthening its position in the biopharmaceutical industry. Recent developments include:

  • Clinical Trial Updates: Aclaris announced positive Phase 2 trial results for Zunsemetinib (ATI-450) in patients with rheumatoid arthritis, demonstrating its potential as a first-in-class therapy.
  • Partnerships and Collaborations: The company entered into a strategic collaboration with a leading pharmaceutical company to co-develop and commercialize its dermatology assets.
  • Regulatory Milestones: Aclaris received Fast Track designation from the FDA for Zunsemetinib, highlighting the therapy’s potential to address unmet medical needs.
  • Corporate Initiatives: Aclaris launched a new patient advocacy program to raise awareness about immuno-inflammatory diseases and support affected individuals.

Investment Considerations

Investors considering Aclaris Therapeutics should weigh the following strengths and risks:

Strengths

  • Innovative Pipeline: Aclaris’s focus on novel mechanisms of action and high-value therapeutic areas positions it for long-term growth.
  • Experienced Leadership: The company’s management team has a proven track record in drug development and commercialization.
  • Strategic Partnerships: Collaborations with leading pharmaceutical companies enhance Aclaris’s ability to bring its therapies to market.

Risks

  • Clinical and Regulatory Uncertainty: The success of Aclaris’s pipeline depends on the outcome of clinical trials and regulatory approvals.
  • Financial Volatility: As a clinical-stage company, Aclaris may face challenges in securing sufficient funding to support its operations.
  • Market Competition: Intense competition from established players could limit Aclaris’s market penetration and revenue growth.

Conclusion

Aclaris Therapeutics, Inc. is a dynamic biopharmaceutical company with a strong focus on addressing unmet medical needs in immuno-inflammatory diseases and dermatological conditions. With a robust pipeline, experienced leadership, and a commitment to innovation, Aclaris is well-positioned to achieve sustainable growth and deliver value to patients and investors alike. However, the company must navigate regulatory challenges, competitive pressures, and financial constraints to realize its full potential. As Aclaris continues to advance its pipeline and expand its market presence, it remains a compelling player in the biopharmaceutical industry.